Timothy J Wilt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11726070/publications.pdf

Version: 2024-02-01

140 papers

16,966 citations

52 h-index 127 g-index

144 all docs

144 docs citations

times ranked

144

18077 citing authors

#	Article	IF	CITATIONS
1	Colonoscopy for Diagnostic Evaluation and Interventions to Prevent Recurrence After Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine, 2022, 175, 416-431.	2.0	11
2	Point-of-Care Ultrasonography: Clearly More Than a Pretty Picture. JAMA Internal Medicine, 2022, , .	2.6	0
3	Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Annals of Internal Medicine, 2022, 175, 701-709.	2.0	34
4	Remdesivir for Adults With COVID-19. Annals of Internal Medicine, 2021, 174, 209-220.	2.0	59
5	Making Narrative Statements to Describe Treatment Effects. Journal of General Internal Medicine, 2021, 36, 196-199.	1.3	6
6	Serum bilirubin and chronic obstructive pulmonary disease (COPD): a systematic review. BMC Pulmonary Medicine, 2021, 21, 33.	0.8	6
7	Major Update: Remdesivir for Adults With COVID-19. Annals of Internal Medicine, 2021, 174, 663-672.	2.0	71
8	Reactions to Recommendations and Evidence About Prostate Cancer Screening Among White and Black Male Veterans. American Journal of Men's Health, 2021, 15, 155798832110221.	0.7	2
9	The Effect of Medical Scribes in Emergency Departments: A Systematic Review. Journal of Emergency Medicine, 2021, 61, 19-28.	0.3	3
10	The intersection of implementation science and community-based suicide prevention research: Opportunities to advance the field. Journal of Affective Disorders, 2021, 290, 237-239.	2.0	3
11	Update Alert: Remdesivir for Adults With COVID-19. Annals of Internal Medicine, 2021, 174, W65.	2.0	5
12	Appropriate Use of Point-of-Care Ultrasonography in Patients With Acute Dyspnea in Emergency Department or Inpatient Settings: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine, 2021, 174, 985-993.	2.0	57
13	Effectiveness and Harms of High-Flow Nasal Oxygen for Acute Respiratory Failure: An Evidence Report for a Clinical Guideline From the American College of Physicians. Annals of Internal Medicine, 2021, 174, 952-966.	2.0	19
14	Orthobiologics in Foot and Ankle Arthrodesis: A Systematic Review. Journal of Foot and Ankle Surgery, 2021, 60, 1029-1037.	0.5	0
15	Update Alert 2: Remdesivir for Adults With COVID-19. Annals of Internal Medicine, 2021, 174, W114-W115.	2.0	4
16	Interventions to Prevent or Delay Long-Term Nursing Home Placement for Adults with Impairments—a Systematic Review of Reviews. Journal of General Internal Medicine, 2020, 35, 2118-2129.	1.3	24
17	Reply to Roderick C.N. van den Bergh, Massimo Valerio, Derya Tilki, and Giorgio Gandagliaa *** Letter to the Editor re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2020.02.009.	0.9	O
18	European Urology, 2020, 76, e69-e70. Effectiveness and harms of high-flow nasal oxygen (HFNO) for acute respiratory failure: a systematic review protocol. BMJ Open, 2020, 10, e034956.	0.8	2

#	Article	IF	Citations
19	Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). European Urology, 2020, 77, 713-724.	0.9	108
20	Effectiveness and harms of mental health treatments in service members and veterans with deployment-related mild traumatic brain injury. Journal of Affective Disorders, 2019, 252, 493-501.	2.0	5
21	Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. Annals of Internal Medicine, 2019, 171, 643-654.	2.0	113
22	Disclosure of Interests and Management of Conflicts of Interest in Clinical Guidelines and Guidance Statements: Methods From the Clinical Guidelines Committee of the American College of Physicians. Annals of Internal Medicine, 2019, 171, 354.	2.0	49
23	The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods. Annals of Internal Medicine, 2019, 170, 863.	2.0	48
24	Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. Aging Male, 2019, 22, 1-11.	0.9	27
25	Agency for Healthcare Research and Quality Evidence-based Practice Center methods provide guidance on prioritization and selection of harms in systematic reviews. Journal of Clinical Epidemiology, 2018, 98, 98-104.	2.4	19
26	Guidelines on Glycemic Targets for Persons With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2018, 320, 1937.	3.8	2
27	Hemoglobin A _{1c} Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Annals of Internal Medicine, 2018, 168, 569.	2.0	314
28	Magnetic Resonance Imaging–Based Prostate Cancer Screening. JAMA Network Open, 2018, 1, e180220.	2.8	0
29	Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Annals of Internal Medicine, 2017, 166, 430.	2.0	280
30	Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine, 2017, 166, 514.	2.0	2,029
31	Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More. European Urology, 2017, 72, 736-737.	0.9	3
32	Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake. Annals of Internal Medicine, 2017, 166, 378.	2.0	3
33	Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older. Annals of Internal Medicine, 2017, 167, 291.	2.0	2
34	Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. New England Journal of Medicine, 2017, 377, 132-142.	13.9	460
35	Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and <scp>PSA</scp> level subgroups: A qualitative study. Health Expectations, 2017, 20, 779-787.	1.1	4
36	Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. European Urology, 2017, 71, 570-581.	0.9	53

#	Article	IF	CITATIONS
37	Systematic Review: Outcomes by Duration of NPO Status prior to Colonoscopy. Gastroenterology Research and Practice, 2017, 2017, 1-9.	0.7	9
38	Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee. Kidney International, 2016, 89, 753-760.	2.6	13
39	Time to Osteoporosis and Major Fracture in Older Men. American Journal of Preventive Medicine, 2016, 50, 727-736.	1.6	14
40	A Value Framework for Cancer Screening: Advice for High-Value Care From the American College of Physicians. Annals of Internal Medicine, 2015, 162, 712-717.	2.0	85
41	PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1566-1574.	2.3	20
42	Effectiveness of Caregiver Interventions on Patient Outcomes in Adults With Dementia or Alzheimer's Disease. Gerontology and Geriatric Medicine, 2015, 1, 233372141559578.	0.8	17
43	Timing of Dialysis Initiation, Duration and Frequency of Hemodialysis Sessions, and Membrane Flux: A Systematic Review for a KDOQI Clinical Practice Guideline. American Journal of Kidney Diseases, 2015, 66, 823-836.	2.1	58
44	KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. American Journal of Kidney Diseases, 2015, 66, 884-930.	2.1	822
45	Screening for Cancer: Advice for High-Value Care From the American College of Physicians. Annals of Internal Medicine, 2015, 162, 718-725.	2.0	165
46	The Paucity of Evidence Supporting Screening for Stages 1–3 CKD in Asymptomatic Patients with or without Risk Factors. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1993-1995.	2.2	12
47	Models in the Development of Clinical Practice Guidelines. Annals of Internal Medicine, 2014, 161, 812.	2.0	39
48	Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence. Journal of the National Cancer Institute, 2014, 106, dju010-dju010.	3.0	25
49	Management of Low Risk and Low PSA Prostate Cancer: Long Term Results from the Prostate Cancer Intervention Versus Observation Trial. Recent Results in Cancer Research, 2014, 202, 149-169.	1.8	9
50	PSA screening for prostate cancer. BMJ, The, 2014, 348, g2559-g2559.	3.0	4
51	Lower urinary tract symptoms in men. BMJ, The, 2014, 349, g4474-g4474.	3.0	50
52	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	5.1	372
53	Prostate cancer screening and the management of clinically localized disease. BMJ, The, 2013, 346, f325-f325.	3.0	73
54	Ascertaining cause of death among men in the Prostate Cancer Intervention Versus Observation Trial. Clinical Trials, 2013, 10, 907-914.	0.7	16

#	Article	IF	CITATIONS
55	The Prostate Cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and Baseline Results of a Randomized Controlled Trial Comparing Radical Prostatectomy With Watchful Waiting for Men With Clinically Localized Prostate Cancer. Journal of the National Cancer Institute Monographs, 2012, 2012, 184-190.	0.9	50
56	Deciding What Type of Evidence and Outcomes to Include in Guidelines. Proceedings of the American Thoracic Society, 2012, 9, 243-250.	3 . 5	9
57	Implementing High-Value, Cost-Conscious Diabetes Mellitus Care Through the Use of Low-Cost Medications and Less-Intensive Glycemic Control Target. Archives of Internal Medicine, 2012, 172, 1610.	4.3	4
58	Changes in Initial Expenditures for Benign Prostatic Hyperplasia Evaluation in the Medicare Population: A Comparison to Overall Medicare Inflation. Journal of Urology, 2012, 187, 1739-1746.	0.2	11
59	Radical Prostatectomy versus Observation for Localized Prostate Cancer. New England Journal of Medicine, 2012, 367, 203-213.	13.9	1,614
60	Evaluative Care Guideline Compliance Is Associated With Provision of Benign Prostatic Hyperplasia Surgery. Urology, 2012, 80, 84-89.	0.5	9
61	Intravesical gemcitabine therapy for nonâ€muscle invasive bladder cancer (NMIBC): a systematic review. BJU International, 2012, 109, 496-505.	1.3	104
62	<i>Serenoa repens</i> monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU International, 2012, 109, 1756-1761.	1.3	93
63	Implications of the prostate intervention versus observation trial (PIVOT). Asian Journal of Andrology, 2012, 14, 815-815.	0.8	2
64	Prostate Cancer Screening: A Review of the Evidence with Clinical Practice Implications., 2012,, 25-49.		0
64	Prostate Cancer Screening: A Review of the Evidence with Clinical Practice Implications., 2012,, 25-49. Targeted therapy for advanced renal cell carcinoma. The Cochrane Library, 2011, 2011, CD006017.	1.5	64
		1.5	
65	Targeted therapy for advanced renal cell carcinoma. The Cochrane Library, 2011, 2011, CD006017. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective		64
65	Targeted therapy for advanced renal cell carcinoma. The Cochrane Library, 2011, 2011, CD006017. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of Clinical Epidemiology, 2011, 64, 1187-1197. Urologist Practice Styles in the Initial Evaluation of Elderly Men With Benign Prostatic Hyperplasia.	2.4	447
65 66 67	Targeted therapy for advanced renal cell carcinoma. The Cochrane Library, 2011, 2011, CD006017. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of Clinical Epidemiology, 2011, 64, 1187-1197. Urologist Practice Styles in the Initial Evaluation of Elderly Men With Benign Prostatic Hyperplasia. Urology, 2011, 77, 535-540. Urologist Compliance With AUA Best Practice Guidelines for Benign Prostatic Hyperplasia in Medicare	2.4 0.5	64 447 16
65 66 67 68	Targeted therapy for advanced renal cell carcinoma. The Cochrane Library, 2011, 2011, CD006017. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of Clinical Epidemiology, 2011, 64, 1187-1197. Urologist Practice Styles in the Initial Evaluation of Elderly Men With Benign Prostatic Hyperplasia. Urology, 2011, 77, 535-540. Urologist Compliance With AUA Best Practice Guidelines for Benign Prostatic Hyperplasia in Medicare Population. Urology, 2011, 78, 3-9. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. BJU International, 2011,	2.4 0.5 0.5	64 447 16 36
65 66 67 68	Targeted therapy for advanced renal cell carcinoma. The Cochrane Library, 2011, 2011, CD006017. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of Clinical Epidemiology, 2011, 64, 1187-1197. Urologist Practice Styles in the Initial Evaluation of Elderly Men With Benign Prostatic Hyperplasia. Urology, 2011, 77, 535-540. Urologist Compliance With AUA Best Practice Guidelines for Benign Prostatic Hyperplasia in Medicare Population. Urology, 2011, 78, 3-9. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. BJU International, 2011, 108, 168-179. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published	2.4 0.5 0.5	64 447 16 36 26

#	Article	IF	Citations
73	5â€Î±â€Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU International, 2010, 106, 1444-1451.	1.3	47
74	Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer. Journal of the National Cancer Institute, 2010, 102, 1826-1834.	3.0	43
75	Finasteride for benign prostatic hyperplasia. The Cochrane Library, 2010, , CD006015.	1.5	63
76	Breast Cancer Screening: From Science to Recommendation. Radiology, 2010, 256, 8-14.	3.6	21
77	Progression of Lower Urinary Tract Symptoms in Older Men: A Community Based Study. Journal of Urology, 2010, 183, 1915-1920.	0.2	60
78	AHRQ Series Paper 4: Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. Journal of Clinical Epidemiology, 2010, 63, 502-512.	2.4	156
79	The Association of Bone Mineral Density with Prostate Cancer Risk in the Osteoporotic Fractures in Men (MrOS) Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 148-154.	1.1	20
80	Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence. Hepatology, 2009, 49, S85-S95.	3.6	57
81	Lower urinary tract symptoms increase the risk of falls in older men. BJU International, 2009, 104, 63-68.	1.3	152
82	The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemporary Clinical Trials, 2009, 30, 81-87.	0.8	146
83	<i>Serenoa repens</i> for benign prostatic hyperplasia., 2009, CD001423.		104
84	Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference. Annals of Internal Medicine, 2009, 150, 111.	2.0	86
85	Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis. Annals of Internal Medicine, 2009, 151, 650.	2.0	163
86	Effect of Exercise on Disorders of Carbohydrate and Lipid Metabolism in Adults With Traumatic Spinal Cord Injury: Systematic Review of the Evidence. Journal of Spinal Cord Medicine, 2009, 32, 361-378.	0.7	40
87	Male urinary incontinence: prevalence, risk factors, and preventive interventions. Reviews in Urology, 2009, 11, 145-65.	0.9	78
88	Antimicrobial urinary catheters: a systematic review. Expert Review of Medical Devices, 2008, 5, 495-506.	1.4	47
89	Excessive Antibiotic Use in Men with Prostatitis. American Journal of Medicine, 2008, 121, 444-449.	0.6	18
90	Association Between Hospital and Surgeon Radical Prostatectomy Volume and Patient Outcomes: A Systematic Review. Journal of Urology, 2008, 180, 820-829.	0.2	124

#	Article	IF	Citations
91	SPCG-4: A Needed START to PIVOTal Data to Promote and ProtecT Evidence-Based Prostate Cancer Care. Journal of the National Cancer Institute, 2008, 100, 1123-1125.	3.0	21
92	Benign prostatic hyperplasia. Part 2â€"Management. BMJ: British Medical Journal, 2008, 336, 206-210.	2.4	13
93	Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer. Annals of Internal Medicine, 2008, 148, 435.	2.0	505
94	Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease?. Annals of Internal Medicine, 2008, 148, 626.	2.0	1
95	Management of chronic hepatitis B. Evidence Report/technology Assessment, 2008, , 1-671.	1.3	12
96	Carbohydrate and lipid disorders and relevant considerations in persons with spinal cord injury. Evidence Report/technology Assessment, 2008, , 1-95.	1.3	14
97	Intermittent versus continuous androgen suppression for prostatic cancer. The Cochrane Library, 2007, , CD005009.	1.5	29
98	Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline. Annals of Internal Medicine, 2007, 147, 639.	2.0	92
99	Erectile Dysfunction. Journal of Urology, 2007, 177, 1675-1681.	0.2	86
100	Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness. BJU International, 2007, 100, 76-81.	1.3	115
101	Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: The MrOS study. Urology, 2006, 68, 804-809.	0.5	136
102	Systematic Review: Antimicrobial Urinary Catheters To Prevent Catheter-Associated Urinary Tract Infection in Hospitalized Patients. Annals of Internal Medicine, 2006, 144, 116.	2.0	276
103	Prevalence and trends of selected urologic conditions for VA healthcare users. BMC Urology, 2006, 6, 30.	0.6	13
104	Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs. Population Health Metrics, 2006, 4, 7.	1.3	80
105	Who uses decision aids? Subgroup analyses from a randomized controlled effectiveness trial of two prostate cancer screening decision support interventions. Health Expectations, 2006, 9, 285-295.	1.1	17
106	Screening for prostate cancer. , 2006, , CD004720.		74
107	Clinically localised prostate cancer. BMJ: British Medical Journal, 2006, 333, 1102-1106.	2.4	20
108	Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical Interventions in Aging, 2006, 1, 389-401.	1.3	20

#	Article	IF	CITATIONS
109	Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: A systematic review of efficacy and adverse effects. Urology, 2005, 66, 780-788.	0.5	69
110	Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology, 2005, 66, 964-970.	0.5	51
111	Effectiveness of Statin Therapy in Adults With Coronary Heart Disease. Archives of Internal Medicine, 2004, 164, 1427.	4.3	231
112	Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU International, 2004, 94, 1263-1270.	1,3	37
113	Randomized trial examining the effect of two prostate cancer screening educational interventions on patient knowledge, preferences, and behaviors. Journal of General Internal Medicine, 2004, 19, 835-842.	1.3	107
114	Measuring patient knowledge of the risks and benefits of prostate cancer screening. Patient Education and Counseling, 2004, 54, 143-152.	1.0	53
115	Reducing PSAnxiety: The importance of noninvasive chronic disease management in prostate cancer detection and treatment. American Journal of Medicine, 2004, 117, 796-798.	0.6	4
116	Is antidepressant plus sildenafil a recipe for priapism?. Postgraduate Medicine, 2004, 116, 11-12.	0.9	26
117	Laser Prostatectomy Versus Transurethral Resection for Treating Benign Prostatic Obstruction: A Systematic Review. Journal of Urology, 2003, 169, 210-215.	0.2	72
118	Prostate cancer intervention. Postgraduate Medicine, 2003, 114, 43-49.	0.9	10
119	Prostate cancer: epidemiology and screening. Reviews in Urology, 2003, 5 Suppl 6, S3-9.	0.9	9
120	Treatment options for benign prostatic hyperplasia. BMJ: British Medical Journal, 2002, 324, 1047-1048.	2.4	8
121	Cost-effectiveness of Gemfibrozil for Coronary Heart Disease Patients With Low Levels of High-Density Lipoprotein Cholesterol <subtitle>The Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial</subtitle> . Archives of Internal Medicine, 2002, 162, 177.	4.3	36
122	Informing patients about prostate cancer screening: identifying and meeting the challenges while the evidence remains uncertain. American Journal of Medicine, 2002, 113, 691-693.	0.6	14
123	TAMSULOSIN FOR TREATING LOWER URINARY TRACT SYMPTOMS COMPATIBLE WITH BENIGN PROSTATIC OBSTRUCTION: A SYSTEMATIC REVIEW OF EFFICACY AND ADVERSE EFFECTS. Journal of Urology, 2002, 167, 177-183.	0.2	57
124	Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. Journal of Urology, 2002, 167, 177-83.	0.2	24
125	Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology, 2001, 57, 727-732.	0.5	123
126	Prostate carcinoma practice patterns. , 2000, 88, 1277-1281.		10

#	Article	IF	CITATIONS
127	Phytotherapy for benign prostatic hyperplasia. Public Health Nutrition, 2000, 3, 459-472.	1.1	84
128	Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. American Journal of Medicine, 2000, 109, 654-664.	0.6	103
129	Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer. Annals of Internal Medicine, 2000, 132, 566.	2.0	357
130	Prostate carcinoma practice patterns. Cancer, 2000, 88, 1277-1281.	2.0	1
131	Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. New England Journal of Medicine, 1999, 341, 410-418.	13.9	3,271
132	Maximal androgen blockade for advanced prostate cancer. The Cochrane Library, 1999, , CD001526.	1.5	59
133	Phytotherapy for benign prostatic hyperplasia. , 1999, , 165-177.		1
134	Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia. JAMA - Journal of the American Medical Association, 1998, 280, 1604.	3.8	341
135	Planning controlled clinical trials. Urology, 1997, 49, 15-26.	0.5	5
136	Carotid Atherosclerosis in Men With Low Levels of HDL Cholesterol. Stroke, 1997, 28, 1919-1925.	1.0	30
137	Correlates and Consequences of Diffuse Atherosclerosis in Men With Coronary Heart Disease. Archives of Internal Medicine, 1996, 156, 1181.	4.3	13
138	Distribution of lipids in 8,500 men with coronary artery disease. American Journal of Cardiology, 1995, 75, 1196-1201.	0.7	219
139	The prostate cancer intervention versus observation trial (PIVOT). A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. Cancer, 1995, 75, 1963-1968.	2.0	22
140	The Prostate Cancer Intervention Versus Observation Trial: A Randomized Trial Comparing Radical Prostatectomy Versus Expectant Management for the Treatment of Clinically Localized Prostate Cancer. Journal of Urology, 1994, 152, 1910-1914.	0.2	156